Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Autoantibodies and pain.
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
12th International Conference on Myasthenia Gravis and Related Disorders
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
Acorda Therapeutics announces Hatch-Waxman extension of AMPYRA® (dalfampridine) sustained-release formulation patent
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Predictors of Fatigue Impact in Persons With Long-Standing Multiple Sclerosis.
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
Differing trends in the incidence of vascular comorbidity in MS and the general population.
Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention-An Update.
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression.
Episode 15 with Professor Ludwig Kappos on the DECIDE trial of daclizumab versus interferon ë_-1a
Optical Coherence Tomography: A Potential Noninvasive Follow-up Tool in Multiple Sclerosis.
Influence of infection on exacerbations of multiple sclerosis.
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor.
Mast cell inflammasome activity in the meninges regulates EAE disease severity.
Episode 9 with Dr. Amit Bar-Or on how pediatric MS can illuminate early mechanisms of the disease
Extended interval dosing of natalizumab in multiple sclerosis.
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.

Pages